{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Carcinoma&page=6", "query": { "condition": "Neck Carcinoma", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 2376, "total_pages": 238, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Carcinoma&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neck+Carcinoma&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T03:17:13.620Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05319730", "title": "A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" }, { "name": "Acetaminophen (or equivalent)", "type": "DRUG" }, { "name": "Dexamethasone (or equivalent)", "type": "DRUG" }, { "name": "Steroid Mouthwash (dexamethasone or equivalent)", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-05-16", "completion_date": "2029-04-10", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 5, "location_summary": "Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "East Syracuse", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319730" }, { "nct_id": "NCT00265941", "title": "Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cetuximab", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "Accelerated Fractionation by Concomitant Boost", "type": "RADIATION" }, { "name": "Intensity-modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 940, "start_date": "2005-11", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 363, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 255 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00265941" }, { "nct_id": "NCT06919666", "title": "NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "NT219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2025-06-12", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 2, "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06919666" }, { "nct_id": "NCT02499328", "title": "Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "AZD9150", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" }, { "name": "AZD5069", "type": "DRUG" }, { "name": "tremelimumab (treme)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 340, "start_date": "2015-08-06", "completion_date": "2025-10-08", "has_results": true, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02499328" }, { "nct_id": "NCT06789172", "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours", "Sarcoma", "HNSCC", "Non Small Cell Lung Cancer", "NSCLC", "Colorectal Cancer (CRC)", "Myxofibrosarcoma (MFS)", "Solitary Fibrous Tumors", "Dedifferentiated Liposarcoma", "Undifferentiated Pleomorphic Sarcoma (UPS)", "Leiomyosarcoma", "Leiomyosarcoma (LMS)", "Gastric Cancer (GC)", "Gastric Cancer Adenocarcinoma Metastatic", "Gastric / Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "OKN4395", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Fasting", "type": "OTHER" }, { "name": "Fed", "type": "OTHER" }, { "name": "H2 Receptor Antagonist", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "Epkin", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2025-01-23", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 3, "location_summary": "Beverly Hills, California • Santa Monica, California • Houston, Texas", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789172" }, { "nct_id": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF-04518600", "type": "DRUG" }, { "name": "PD 0360324", "type": "DRUG" }, { "name": "CMP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2015-11-09", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 57, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02554812" }, { "nct_id": "NCT01088802", "title": "Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Oropharynx" ], "interventions": [ { "name": "IMRT", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 60, "start_date": "2010-03", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088802" }, { "nct_id": "NCT00002930", "title": "PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Esophageal Cancer", "Lung Cancer" ], "interventions": [ { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "1996-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002930" }, { "nct_id": "NCT05280314", "title": "Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "IO102-IO103", "type": "DRUG" }, { "name": "Pembrolizumab KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IO Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-12-21", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Richmond, Virginia", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05280314" }, { "nct_id": "NCT05592626", "title": "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Genital Neoplasm, Female", "Urogenital Neoplasms", "Lung Neoplasm", "Neoplasms by Site", "Papillomavirus Infection", "Epstein-Barr Virus Infections", "Carcinoma", "Neoplasms", "Vulvar Neoplasms", "Vulvar Diseases", "Abdominal Neoplasm", "NSCLC (Non-small Cell Lung Cancer)", "Colorectal Cancer" ], "interventions": [ { "name": "STAR0602", "type": "DRUG" }, { "name": "Irinotecan (Camptosar)", "type": "COMBINATION_PRODUCT" }, { "name": "Docetaxel (Taxotere)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Marengo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 366, "start_date": "2023-01-04", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-09T03:17:13.620Z", "location_count": 13, "location_summary": "Sacramento, California • Celebration, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592626" } ] }